How to buy Nautilus Biotechnology, Inc stock on Stash
- Enter the amount you'd like to invest in Nautilus Biotechnology, Inc stock, then proceed to checkout. Stash allows...
- Choose a Stash plan and set up your investment account in just a few minutes. Stash offers three subscription plans:...
- Once you’ve finished your account, your Nautilus Biotechnology, Inc...
Full Answer
Is Nautilus biotechnology (nut) stock a buy or sell?
How to buy Nautilus Biotechnology, Inc stock on Stash 1. Enter the amount you'd like to invest in Nautilus Biotechnology, Inc stock, then proceed to checkout. Stash allows... 2. Choose a Stash plan and set up your investment account in just a few …
Why did Nautilus biotechnology rise 50% Thursday morning?
Apr 01, 2022 · The Nautilus Biotechnology, Inc. stock price gained 0.25% on the last trading day (Tuesday, 19th Apr 2022), rising from $3.93 to $3.94. During the day the stock fluctuated 4.90% from a day low at $3.88 to a day high of $4.07. The price has fallen in 7 of the last 10 days and is down by -13.79% for this period. Volume fell on the last day by -83 ...
Where is Nautilus Biotechnology located?
Apr 08, 2022 · Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add. $3.91. -0.10 (-2.49%) (As of 04/21/2022 02:02 PM ET) Today's Range. $3.87.
Who is Nautilus biotechnology's new general counsel?
Apr 03, 2022 · 4 equities research analysts have issued 1 year price targets for Nautilus Biotechnology's stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Nautilus Biotechnology's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 114.0% from the stock's current price.
Can I buy Nautilus biotechnology stock?
, you can buy Nautilus Biotechnology, Inc stock in any dollar amount, or any other fund or stock you know on Stash.
Is Nautilus biotechnology publicly traded?
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome. June 09, 2021 22:05 ET | Source: Nautilus Biotechnology Inc. Nautilus Biotechnology Inc. Publicly traded company renamed Nautilus Biotechnology, Inc.Jun 9, 2021
How do I buy Nautilus stock?
How to buy shares in NautilusCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Is Nautilus stock a good buy?
Nautilus has received a consensus rating of Buy.
Did Jeff Bezos invest in Nautilus?
Amazon Founder Jeff Bezos' venture-capital firm Bezos Expeditions invested in Nautilus, in addition to Amazon. “I don't have further comments in terms of their motivations in the future,” Patel said, although he added that that might change.Aug 5, 2021
What tech stock is Jeff Bezos buying?
Jeff Bezos reportedly invests in Altos Labs, the latest startup trying to extend human life. Amazon ex-CEO Jeff Bezos has been looking to space for humanity's future. But the world's richest man is also trying to extend humanity's lifespan here on Earth, according to a report in MIT's Technology Review.Sep 7, 2021
Will Nautilus stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Nautilus Inc have a median target of 11.50, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +215.07% increase from the last price of 3.65.
What does Nautilus biotechnology do?
Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
Will NLS stock go up?
On average, Wall Street analysts predict that NAUTILUS's share price could reach $10.75 by Feb 10, 2023. The average NAUTILUS stock price prediction forecasts a potential upside of 184.39% from the current NLS share price of $3.78.
Is Nautilus a buy Zacks?
The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Why is Nautilus stock so low?
After the stock soared in 2020, the stock is down 30% year to date, as investors brace for a slowdown following the pandemic. One analyst downgraded the stock to hold from buy, which probably fueled the sell-off even further.Aug 10, 2021
Is Bowflex on the stock market?
Bowflex of America changed its name to Bowflex, Inc, and became a public company on the Toronto Stock Exchange. In 1999 the company changed its name to Direct Focus, Inc. and initiated an IPO on Nasdaq.
Who is on Nautilus Biotechnology's Insider Roster?
The list of insiders at Nautilus Biotechnology includes Anna Mowry , Matthew B Murphy , Matthew L Posard , Matthew S Mcilwain , Perceptive Advi...
Which Nautilus Biotechnology insiders have been buying company stock?
The following insiders have purchased Nautilus Biotechnology stock in the last 24 months: Anna Mowry ($134,925.00), Matthew B Murphy ($37,800.0...
How much insider buying is happening at Nautilus Biotechnology?
Insiders have purchased a total of 579,755 Nautilus Biotechnology shares in the last 24 months for a total of $3,005,139.79 bought.
Is Nautilus Biotechnology a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 2 ho...
Are investors shorting Nautilus Biotechnology?
Nautilus Biotechnology saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 1,660,00...
When is Nautilus Biotechnology's next earnings date?
Nautilus Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, May 26th 2022. View our earnings forecast for...
How were Nautilus Biotechnology's earnings last quarter?
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Monday, November, 1st. The company reported ($0.12) EPS for the quarter,...
What price target have analysts set for NAUT?
4 analysts have issued 1 year target prices for Nautilus Biotechnology's shares. Their forecasts range from $8.00 to $13.00. On average, they antic...
Who are Nautilus Biotechnology's key executives?
Nautilus Biotechnology's management team includes the following people: Mr. Sujal M. Patel , Co-Founder & CEO (Age 46) ( LinkedIn Profile ) Mr....
Who are some of Nautilus Biotechnology's key competitors?
Some companies that are related to Nautilus Biotechnology include Olink Holding AB (publ) (OLK) , Cytek BioSciences (CTKB) , Cue Health (HLTH) ,...
What is Nautilus Biotechnology's stock symbol?
Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT."
Who are Nautilus Biotechnology's major shareholders?
Nautilus Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advis...
Signals & Forecast
A buy signal was issued from a pivot bottom point on Wednesday, February 23, 2022, and so far it has risen 8.43%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Nautilus Biotechnology, Inc.
Support, Risk & Stop-loss
Nautilus Biotechnology, Inc. finds support from accumulated volume at $3.82 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Nautilus Biotechnology, Inc. stock A Buy?
Nautilus Biotechnology, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are very positive buying more shares than they are selling in Nautilus Biotechnology, Inc
In the last 29 trades there were 22.9 million shares bought and 210 thousand shares sold. The last trade was done 66 days ago by Mallick Parag who sold 210 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Insider Buying and Selling by Quarter
Want to know when executives and insiders are buying or selling Nautilus Biotechnology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.
Who is on Nautilus Biotechnology's Insider Roster?
The list of insiders at Nautilus Biotechnology includes Anna Mowry, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, and Sujal M Patel. Learn more on NAUT's insiders
How much insider buying is happening at Nautilus Biotechnology?
Insiders have purchased a total of 529,755 Nautilus Biotechnology shares in the last 24 months for a total of $2,825,139.79 bought.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome.
3.3 Analyst's Opinion
Nautilus Biotechnology has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Is Nautilus Biotechnology a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock.
Are investors shorting Nautilus Biotechnology?
Nautilus Biotechnology saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 1,660,000 shares, a decrease of 25.9% from the January 15th total of 2,240,000 shares. Based on an average daily volume of 457,600 shares, the days-to-cover ratio is presently 3.6 days.
When is Nautilus Biotechnology's next earnings date?
Nautilus Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for Nautilus Biotechnology.
How can I listen to Nautilus Biotechnology's earnings call?
Nautilus Biotechnology will be holding an earnings conference call on Thursday, February 24th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Nautilus Biotechnology's earnings last quarter?
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its quarterly earnings results on Monday, November, 1st. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.02. View Nautilus Biotechnology's earnings history.
Nautilus Biotechnology (NAUT)
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Nautilus Biotechnology, Inc. - Hold
Zacks' proprietary data indicates that Nautilus Biotechnology, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the NAUT shares relative to the market in the next few months. In addition, Nautilus Biotechnology, Inc.
Chart for NAUT
Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.
Nautilus Biotechnology Insider Trading History Chart
This chart shows the insider buying and selling history at Nautilus Biotechnology by year and by quarter.
Nautilus Biotechnology Share Price & Price History
This chart shows the closing price history over time for NAUT up to the past year.
SEC Filings (Institutional Ownership Changes) for Nautilus Biotechnology (NASDAQ:NAUT)
33.00% of Nautilus Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
What is Weisslaw LLP investigating?
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III ("AR...
Is Nautilus publicly traded?
Nautilus Biotechnology is emerging as Seattle's newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biom...
NAUT earnings per share forecast
What is NAUT 's earnings per share in the next 3 years based on estimates from 2 analyst s?
NAUT revenue forecast
What is NAUT 's revenue in the next 3 years based on estimates from 2 analyst s?